Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial

Australian and New Zealand Journal of Psychiatry

Volumn 51, Issue 8, 2017, Pages 829-840

  Dean, Olivia M ^a,b   Kanchanatawan, Buranee ^c   Ashton, Melanie ^a,b   Mohebbi, Mohammadreza ^a   Ng, Chee Hong ^b   Maes, Michael ^c   Berk, Lesley ^a   Sughondhabirom, Atapol ^c   Tangwongchai, Sookjaroen ^c   Singh, Ajeet B ^a   McKenzie, Helen ^a   Smith, Deidre J ^b   Malhi, Gin S ^d,e   Dowling, Nathan ^b   Berk, Michael ^a,b,f,g  

^a DEAKIN UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d UNIVERSITY OF SYDNEY   (Australia)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

^f THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

adjunctive; clinical trial; depression; inflammation; Minocycline

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; MINOCYCLINE; MOOD STABILIZER; NEUROLEPTIC AGENT; PLACEBO; ANTIINFECTIVE AGENT;

ADJUVANT THERAPY; ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EFFECT SIZE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; QUALITY OF LIFE ASSESSMENT; QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RANGE OF IMPAIRED FUNCTIONING TOOL; SOCIAL AND OCCUPATIONAL FUNCTIONING ASSESSMENT SCALE; TREATMENT OUTCOME; COMBINATION DRUG THERAPY; MIDDLE AGED; OUTCOME ASSESSMENT; PROOF OF CONCEPT; PSYCHOLOGY; QUALITY OF LIFE; SATISFACTION;

ADULT; ANTI-BACTERIAL AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; OUTCOME ASSESSMENT (HEALTH CARE); PERSONAL SATISFACTION; PROOF OF CONCEPT STUDY; QUALITY OF LIFE;

EID: 85025128729     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867417709357     Document Type: Article

References (26)

1. Barber ME, (2012) Recovery as the new medical model for psychiatry. Psychiatric Services 63: 277-279.
2. Berk M, Malhi GS, Gray LJ, et al. (2013) The promise of N-acetylcysteine in neuropsychiatry. Trends in Pharmacological Sciences 34: 167-177.
3. Bilici M, Efe H, Koroglu MA, et al. (2001) Antioxidative enzyme activities and lipid peroxidation in major depression: Alterations by antidepressant treatments. Journal of Affective Disorders 64: 43-51.
4. Dean OM, Data-Franco J, Giorlando F, et al. (2012) Minocycline: Therapeutic potential in psychiatry. CNS Drugs 26: 391-401.
5. Dean OM, Maes M, Ashton M, et al. (2014) Protocol and rationale-The efficacy of minocycline as an adjunctive treatment for major depressive disorder: A double blind, randomised, placebo controlled trial. Clinical Psychopharmacology and Neuroscience 12: 180-188.
6. Faridhosseini F, Sadeghi R, Farid L, et al. (2014) Celecoxib: A new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Human Psychopharmacology 29: 216-223.
7. Fernandes BS, Dean OM, Dodd S, et al. (2016) N-Acetylcysteine in depressive symptoms and functionality: A systematic review and meta-analysis. Journal of Clinical Psychiatry 77: e457-e466.
8. Fournier JC, DeRubeis RJ, Hollon SD, et al. (2010) Antidepressant drug effects and depression severity: A patient-level meta-analysis. Journal of the American Medical Association 303: 47-53.
9. Ghaleiha A, Alikhani R, Kazemi MR, et al. (2016) Minocycline as adjunctive treatment to risperidone in children with autistic disorder: A randomized, double-blind placebo-controlled trial. Journal of Child and Adolescent Psychopharmacology 26: 784-791.
10. Goulden V, Glass D, Cunliffe WJ, (1996) Safety of long-term high-dose minocycline in the treatment of acne. British Journal of Dermatology 134: 693-695.
11. Homsi S, Federico F, Croci N, et al. (2009) Minocycline effects on cerebral edema: Relations with inflammatory and oxidative stress markers following traumatic brain injury in mice. Brain Research 1291: 122-132.
12. Kernt M, Neubauer AS, Eibl KH, et al. (2010) Minocycline is cytoprotective in human trabecular meshwork cells and optic nerve head astrocytes by increasing expression of XIAP, survivin, and Bcl-2. Clinical Ophthalmology 4: 591-604.
13. Kim BJ, Kim MJ, Park JM, et al. (2009) Reduced neurogenesis after suppressed inflammation by minocycline in transient cerebral ischemia in rat. Journal of the Neurological Sciences 279: 70-75.
14. Kim SS, Kong PJ, Kim BS, et al. (2004) Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells. Archives of Pharmacal Research 27: 314-318.
15. Kohler O, Benros ME, Nordentoft M, et al. (2014) Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 71: 1381-1391.
16. Maes M, (1995) Evidence for an immune response in major depression: A review and hypothesis. Progress in Neuro-Psychopharmacology & Biological Psychiatry 19: 11-38.
17. Maes M, De Vos N, Pioli R, et al. (2000) Lower serum vitamin E concentrations in major depression: Another marker of lowered antioxidant defenses in that illness. Journal of Affective Disorders 58: 241-246.
18. Maes M, Kubera M, Leunis JC, et al. (2013) In depression, bacterial translocation. drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged neoepitopes. Acta Psychiatrica Scandinavica 127: 344-354.
19. Malhi GS, Bassett D, Boyce P, et al. (2015) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Australian and New Zealand Journal of Psychiatry 49: 1-185.
20. Miyaoka T, Wake R, Furuya M, et al. (2012) Minocycline as adjunctive therapy for patients with unipolar psychotic depression: An open-label study. Progress in Neuro-Psychopharmacology & Biological Psychiatry 37: 222-226.
21. Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, et al. (2008) Desipramine or glutamate antagonists synergized the antidepressant-like actions of intra-nucleus accumbens infusions of minocycline in male Wistar rats. Progress in Neuro-Psychopharmacology & Biological Psychiatry 32: 1660-1666.
22. O'Leary OF, Cryan JF, (2014) A ventral view on antidepressant action: Roles for adult hippocampal neurogenesis along the dorsoventral axis. Trends in Pharmacological Sciences 35: 675-687.
23. Oya K, Kishi T, Iwata N, (2014) Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: A systematic review and meta-analysis of randomized controlled trials. Human Psychopharmacology 29: 483-491.
24. Rush AJ, Trivedi MH, Wisniewski SR, et al. (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR∗D report. American Journal of Psychiatry 163: 1905-1917.
25. Yrjanheikki J, Keinanen R, Pellikka M, et al. (1998) Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proceedings of the National Academy of Sciences of the United States of America 95: 15769-15774.
26. Zheng LS, Kaneko N, Sawamoto K, (2015) Minocycline treatment ameliorates interferon-alpha-induced neurogenic defects and depression-like behaviors in mice. Frontiers in Cellular Neuroscience 9: 5.